Press Release: Integra LifeSciences Reports Third -3-
Press Release: Integra LifeSciences Reports Third -3-
新聞稿：Integra LifeSciences報告第三季度-3-
(In thousands, except per share amounts)
(單位為千，每股除外)
Three Months Ended September 30,
2021 2020
--------------------- -------------------
Total revenues, net $ 386,861 $ 370,232
Costs and expenses:
Cost of goods sold 144,468 134,811
Research and development 25,831 19,460
Selling, general and
administrative 156,010 150,076
Intangible asset amortization 4,113 8,343
------------- ------------
Total costs and expenses 330,422 312,690
------------- ------------
Operating income 56,439 57,542
------------- ------------
Interest income 1,786 2,273
Interest expense (12,192) (20,796)
Gain (loss) from sale of
business (230) --
Other income, net 4,985 2,492
------------- ------------
Income before income taxes 50,788 41,511
Income tax expense 7,559 9,174
Net income $ 43,229 $ 32,337
------------- ------------
Net income per share:
Diluted net income per share $ 0.51 $ 0.38
------------- ------------
Weighted average common shares
outstanding for diluted net
income per share 85,447 84,752
截至9月30日的三個月， 2021 2020 --------------------- ------------------- 總收入，淨額386,861美元370,232美元成本和費用：銷貨成本144,468 134,811研發25,831 19,460銷售、一般和行政156,010 150,076無形資產攤銷4,113 8,343 ------------- ------------ 總成本和支出330,422 312,690 ------------- ------------ 營業收入56,439 57,542 ------------- ------------ 利息收入1,7862,273利息支出(12,192)(20,796)出售的收益(損失)商界(230)--其他收入，淨額4985 2492 ------------- ------------ 所得税前收入50,788 41,511所得税支出7559 9174淨收入43,229美元32,337美元 ------------- ------------ 每股淨收益：稀釋後每股淨收益$0.51$0.38 ------------- ------------ 加權平均普通股未清償稀釋淨額每股收益85,447 84,752
The following table presents revenues disaggregated by the major sources for the three months ended September 30, 2021 and 2020 (amounts in thousands):
下表列出了截至2021年9月30日和2020年9月30日的三個月按主要來源分列的收入(以千為單位)：
Three Months Ended September 30,
2021 2020 Change
------------------ ----------- ---------
Neurosurgery 199,210 189,674 5.0%
Instruments 57,287 49,649 15.4%
---------- --------- -----
Total Codman
Specialty Surgical 256,497 239,323 7.2%
Wound Reconstruction and
Care 99,744 82,115 21.5%
Extremity Orthopedics -- 21,922 --
Private Label 30,620 26,872 13.9%
---------- --------- -----
Total Tissue
Technologies 130,364 130,909 (0.4)%
---------- --------- -----
Total reported
revenues 386,861 370,232 4.5%
========== ========= =====
Impact of changes in
currency exchange rates (1,011) --
Less contribution of
revenues from
acquisitions (16,842) --
Less contribution of
revenues from divested
products (249) (22,137)
Less contribution of
revenues from
discontinued products (2,139) (4,344)
---------- --------- ---------
Total organic
revenues(1) $ 366,620 $ 343,751 6.7%
---------- --------- -----
截至9月30日的三個月，2021年到2020年的變化 ------------------ ----------- --------- 神經外科199,210 189,6745.0%儀器57,287 49,649 15.4% ---------- --------- ----- 全科德曼(Total Codman)專科外科256,497,239,323 7.2%傷口重建和護理99,744 82,115 21.5%四肢骨科--21,922--自有品牌30,620 26,872 13.9% ---------- --------- ----- 總組織數科技130,364 130,909(0.4)% ---------- --------- ----- 報告總數收入386,861 370,232 4.5% ========== ========= ===== 發生變化的影響貨幣匯率(1011)--減少以下方面的貢獻從以下來源獲得的收入收購(16,842)--減少以下方面的貢獻剝離的收入產品系列(249)(22,137)減少以下方面的貢獻從以下來源獲得的收入停產產品(2139)(4344) ---------- --------- --------- 全有機收入(1)366,620美元343,751 6.7% ---------- --------- -----
(1) Organic revenues have been adjusted to exclude foreign currency (current period), acquisitions and to account for divested and discontinued products.
(1)有機收入進行了調整，不包括外幣(當期)、收購，並計入了剝離和停產的產品。
Items included in GAAP net income and location where each item is recorded are as follows:
GAAP淨收入中包含的項目和每個項目的記錄地點如下：
(In thousands)
(單位：千)
Three Months Ended September 30, 2021
截至2021年9月30日的三個月
Total Amort.(
Item Amount COGS(a) SG&A(b) R&D(c) d) OI&E(e) Tax(f)
Acquisition,
divestiture and
integration-related
charges(1) 2,637 1,954 2,166 (160) -- (1,323) --
Structural
Optimization
charges 6,696 2,970 2,235 1,492 -- -- --
EU Medical Device
Regulation charges 7,077 907 1,985 4,185 -- -- --
Discontinued product
lines charges 23 23 -- -- -- -- --
Intangible asset
amortization
expense 20,248 16,135 -- -- 4,113 -- --
Estimated income tax
impact from above
adjustments and
other items (6,853) -- -- -- -- -- (6,853)
-------------------- ------ ------ ----- ----- ------ ------ ------
Total adjustments $29,828 $21,989 $ 6,386 $5,517 $ 4,113 $(1,323) $(6,853)
-------------------- ------ ------ ----- ----- ------ ------ ------
Depreciation expense 9,873 -- -- -- -- -- --
a) COGS - Cost of goods sold
b) SG&A - Selling, general and administrative
c) R&D - Research & development
d) Amort. - Intangible asset amortization
e) OI&E - Other income & expense
f) Tax - Income tax expense (benefit)
道達爾·阿莫特(Total Amort)。項目金額COGS(A)SG&A(B)R&D(C)d)OI&E(E)税(F)收購，資產剝離和與集成相關的收費(1)2,637 1,954 2,166(160)--(1,323)--結構性最佳化收費6,696 2,970 2,235 1,492歐盟醫療器械監管收費7,077 907 1,9854,185停產產品線路收費23 23無形資產攤銷費用20,248 16,135-4,113估計所得税來自上方的影響調整和其他項目(6853)-(6853)-------------------- ------ ------ ----- ----- ------ ------ ------ 調整總額$29,828$21,989$6,386$5,517$4,113$(1,323)$(6,853)-------------------- ------ ------ ----- ----- ------ ------ ------ 折舊費9873A)COGS--售出商品成本B)SG&A-銷售、一般和行政C)研發--研發D)阿莫特。-無形資產攤銷E)OI&E--其他收入和費用F)税--所得税費用(福利)
(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics and ACell acquisitions and the divestiture of Extremity Orthopedics and includes banking, legal, consulting, systems, and other income and expenses.
(1)收購、剝離和整合相關費用與Codman神經外科、Arkis生物科學、反彈治療和ACell收購以及剝離Extremity Orthopedics有關，包括銀行、法律、諮詢、系統和其他收入和支出。
Three Months Ended September 30, 2020
截至2020年9月30日的三個月
(In thousands)
(單位：千)
Total COGS SG&A R&D Amort. OI&E
Item Amount (a) (b) (c) (d) (e) Tax (f)
Structural
optimization
charges 4,543 491 3,875 177 -- -- --
Acquisition and
integration-related
charges(1) 7,148 3,871 2,596 682 -- -- --
COVID-19 related
charges (193) 2 (195) -- -- -- --
EU Medical Device
Regulation charges 2,399 1,529 871 -- -- -- --
Discontinued product
line charges 999 999 -- -- -- -- --
Intangible asset
amortization
expense 20,180 11,837 -- -- 8,343 -- --
Convertible debt
non-cash interest 4,295 -- -- -- -- 4,295 --
Expenses related to
debt refinancing 3,428 -- -- -- -- 3,428 --
Estimated income tax
impact from above
adjustments and
other items (7,433) -- -- -- -- -- (7,433)
--------------------- ------ ------ ----- --- ------ ----- ------
Total adjustments $35,366 $18,729 $7,147 $859 $ 8,343 $7,723 $(7,433)
--------------------- ------ ------ ----- --- ------ ----- ------
Depreciation expense 10,538
a) COGS - Cost
of goods sold
b) SG&A -
Selling,
general and
administrative
c) R&D -
Research &
Development d)
Amort. -
Intangible
asset
amortization
e) OI&E -
Other income &
expense f) Tax
- Income tax
expense
(benefit)
COGS SG&A R&D Amort合計OI&E項目金額(A)(B)(C)(D)(E)税(F)結構性優化收費4,543 491 3,875 177收購和與集成相關的收費(1)7,148 3,871 2,596 682新冠肺炎相關收費(193)2(195)歐盟醫療器械監管收費2,399 1,529 871停產產品線路收費999 999無形資產攤銷費用20,180 11,837-8,343可轉換債券非現金利息4,295-4,295--與以下項目相關的費用債務再融資3,428-3,428--估計所得税來自上方的影響調整和其他項目(7,433)-(7,433)--------------------- ------ ------ ----- --- ------ ----- ------ 調整總額$35,366$18,729$7,147$859$8,343$7,723$(7,433)--------------------- ------ ------ ----- --- ------ ----- ------ 折舊費用10,538A)COGS--成本已售出商品的百分比B)SG&A-銷售，一般和行政性C)研發-研究與開發發展d)阿莫特。-無形的資產攤銷E)OI&E-其他收入&費用f)税-所得税費用(利益)
(1) Acquisition and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences and Rebound Therapeutics acquisitions and include banking, legal, consulting, systems, and other expenses.
(1)與收購和整合相關的費用與Codman神經外科、Arkis生物科學和反彈治療公司的收購有關，包括銀行、法律、諮詢、系統和其他費用。
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO ADJUSTED EBITDA
非GAAP調整的對賬-GAAP淨收入與調整後的EBITDA
(UNAUDITED)
(未經審計)
(In thousands)
(單位：千)
Three Months Ended September 30,
------------------------------------------
2021 2020
--------------------- -------------------
GAAP net income 43,229 32,337
Non-GAAP adjustments:
Depreciation and intangible
asset amortization expense 30,121 30,718
Other (income) expense, net (3,432) (2,492)
Interest expense, net 10,406 10,800
Income tax expense 7,559 9,174
Discontinued product lines
charges 23 999
Structural optimization charges 6,696 4,543
EU Medical Device Regulation
charges 7,077 2,399
Acquisition, divestiture and
integration-related charges(1) 2,637 7,148
COVID-19 related charges -- (193)
Convertible debt non-cash
interest (2) -- 4,295
Expenses related to debt
refinancing -- 3,428
----------------- ----------------
Total of non-GAAP
adjustments 61,087 70,819
----------------- ----------------
Adjusted EBITDA $ 104,315 $ 103,156
------------- ------------
截至9月30日的三個月， ------------------------------------------ 2021 2020 --------------------- ------------------- 公認會計準則淨收益43,229 32,337非GAAP調整：折舊與無形資產資產攤銷費用30,121 30,718其他(收入)費用，淨額(3432)(2492)利息支出，淨額10,406,100,800所得税支出7559 9174停產產品線收費23999結構優化費用6696 4543歐盟醫療器械法規收費7,077,399收購、剝離和與融合有關的收費(1)2637 7148新冠肺炎相關收費--(193)可轉換債務非現金利息(2)--4,295與債務有關的費用再融資--3,428 ----------------- ---------------- 非GAAP合計調整61,087 70,819 ----------------- ---------------- 調整後的EBITDA$104,315$103,156 ------------- ------------
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。